Clementia Pharm Forecasted to Earn Q3 2017 Earnings of ($0.32) Per Share (CMTA)
Clementia Pharm (NASDAQ:CMTA) – Investment analysts at Leerink Swann issued their Q3 2017 EPS estimates for Clementia Pharm in a research note issued to investors on Monday. Leerink Swann analyst J. Schwartz expects that the company will post earnings per share of ($0.32) for the quarter. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Clementia Pharm’s Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($4.57) EPS, FY2018 earnings at ($1.17) EPS, FY2019 earnings at ($1.20) EPS, FY2020 earnings at ($1.47) EPS and FY2021 earnings at ($0.40) EPS.
Several other research analysts have also weighed in on the stock. Morgan Stanley began coverage on shares of Clementia Pharm in a research note on Monday. They set an “overweight” rating and a $27.00 target price for the company. Wedbush initiated coverage on shares of Clementia Pharm in a research note on Monday. They issued an “outperform” rating and a $26.00 price objective for the company.
Shares of Clementia Pharm (NASDAQ:CMTA) opened at 16.01 on Wednesday. The stock’s market capitalization is $488.74 million. Clementia Pharm has a 52-week low of $15.05 and a 52-week high of $18.95. The firm’s 50-day moving average is $14.97 and its 200 day moving average is $14.97.
Clementia Pharm Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharm and related companies with Analyst Ratings Network's FREE daily email newsletter.